| ZBRA |
Report |
Non-GAAP diluted EPS |
BEAT |
pred ~$4.60 vs. cons ~$4.35 |
MEDIUM |
| ZBRA |
Report |
Revenue |
BEAT |
pred ~$1.52B vs. cons ~$1.498B |
MEDIUM |
| ZBRA |
Report |
Adj. EBITDA margin |
IN-LINE |
pred ~21.3% vs. cons ~21.0% |
MEDIUM |
| ZBRA |
Guide |
FY26 non-GAAP EPS (raise #3?) |
BETTER |
guide ~$18.90 vs. cons ~$18.60 (FY26) |
MEDIUM |
| ZBRA |
Guide |
Q3'26 revenue guide |
BETTER |
guide ~$1.52B vs. cons ~$1.50B (Q3'26) |
LOW |
| ZBRA |
Guide |
Memory/DRAM margin mitigation commentary |
UNCHANGED |
reaffirm ~2pt GM headwind fully offset, ~22% FY EBITDA margin vs. cons ~22% (FY26 H2) |
MEDIUM |
| ZBRA |
Guide |
Organic revenue growth |
BETTER |
pred ~5% vs. cons ~4% (Q2'26) |
LOW |
| ZBRA |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.0% |
— |
LOW |
| ZBRA |
Return |
5-day cumulative residual |
+0.5% (FADE) |
Beat-and-raise likely delivers a modest initial pop, but the stock already ran ~11% into the print (264->293) with consensus only at the guide midpoint, so much is discounted. Out-period math is the drag: memory/DRAM costs step up sequentially in Q2 and the back half, so even a headline FY EPS raise embeds a richer H2 mitigation burden and un-confirmed supply allocation. That caps upside revisions and invites profit-taking, so the day-1 gain partly fades over the week. |
LOW |